BioSpace News Archive

Biotech Bay

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults

Scilex Holding Company announced expected plans to launch Gloperba, its novel liquid colchicine formulation, in the first half of 2024 with a launch price of $595 per 150ml bottle.

March 5, 2024
·
9 min read
Biotech Bay

Shasqi to Present New Data at 2024 World ADC London Conference

Shasqi, Inc. announced that Founder & Chief Executive Officer José M. Mejía Oneto, MD, PhD, will present at the 14th Annual World ADC Conference in London, United Kingdom on Tuesday March 12th at 11:00am GMT.

March 5, 2024
·
2 min read
BioMidwest

DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador

DaVita Inc, a leading provider of kidney care services, announced that it has agreed to terms on the expansion of its international operations in Brazil and Colombia, and its entry into Chile and Ecuador.

March 5, 2024
·
3 min read
Biotech Beach

Phenomenex Introduces Biozen dSEC-7, A New Way to Study AAVs with Unprecedented Speed and Efficiency

Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, proudly announces its newest Size Exclusion Chromatography product, Biozen dSEC-7, for the analysis of AAVs.

March 5, 2024
·
2 min read
Drug Development

Grace Science, LLC Announces First Patient Treated in Phase 1/2/3 Trial of GS-100, an AAV9 Gene Therapy for NGLY1 Deficiency

Grace Science, LLC announced today that the first patient was dosed in an open-label Phase 1/2/3 clinical trial of GS-100, an AAV9 gene replacement therapy for the treatment of NGLY1 Deficiency.

March 5, 2024
·
2 min read
Er-Kim Selected to Join the World Economic Forum’s New Champions Community

Er-Kim announced it has been selected to join the World Economic Forum’s New Champions Community, a group of dynamic forward-looking companies that are championing new business models, emerging technologies, and sustainable growth strategies.

March 5, 2024
·
2 min read
Drug Development

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata.

March 5, 2024
·
7 min read
FDA

Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

Cleerly ® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System.

March 5, 2024
·
3 min read
Drug Development

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV.

March 5, 2024
·
7 min read
Deals

Enlyte and Former Genex Leaders Reach Agreement to Create New IME Business

Enlyte and its Board of Directors have made the strategic decision to transfer its Independent Medical Examination (IME) business and more than 350 employees from Enlyte to the creation of a new, stand-alone IME company, Emperion, Inc.

March 5, 2024
·
2 min read